Shots:

• The collaboration leverages Adaptive’s immune medicine platform for the identification of virus-neutralizing Abs with Amgen's proficiency in immunology and novel Abs development
• Adaptive extends immune medicine platform to discover Abs from recovered COVID-19 patients- which enables the company to identify Abs from survivors of COVID-19 to select those that neutralize SARS-CoV-2
• Amgen will leverage its expertise to select- develop and manufacture Abs designed to bind and neutralize SARS-CoV-2. Additionally- both the companies have signed an MoU enabling the partners to commence the work immediately and are planning to execute a collaboration and license agreement

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Biospace